{"id":"W4310163262","doi":"10.1182/blood-2022-160319","title":"A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Internal medicine; Phases of clinical research; Lymphoma; Oncology; Gastroenterology; Multiple myeloma; Clinical trial; Materials science","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001545769,0.001553256,0.002615514,0.0004817085,0.0005087641,0.001616412,0.001221314,0.001311235,0.004866304],"category_scores_gemma":[0.0008881866,0.0007905083,0.002139737,0.0004647672,0.000860792,0.0009918744,0.0004925773,0.004120993,0.001454503],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001778985,"about_ca_system_score_gemma":0.002172532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001993709,"about_ca_topic_score_gemma":0.005015329,"domain_scores_codex":[0.999575,0.0001649259,0.00002249175,0.00008992763,0.00004470861,0.0001029344],"domain_scores_gemma":[0.9992672,0.00008372407,0.00009464325,0.00005946195,0.00006284772,0.0004320365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7706175,0.102546,0.005195451,0.001067188,0.003095503,0.0002900512,0.000376425,0.001870827,0.02143045,0.0002865603,0.004940375,0.08828369],"study_design_scores_gemma":[0.7176055,0.2690905,0.007040016,0.00004983418,0.0006366226,0.0002231846,0.00007992788,0.0008303651,0.000979099,0.0002386467,0.003190577,0.00003567791],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850723,0.004231659,0.0005768168,0.0007856913,0.0003274796,0.004488244,0.001710894,0.0001586948,0.002648162],"genre_scores_gemma":[0.9812599,0.002962556,0.002518255,0.002169824,0.0002496213,0.004775934,0.003146528,0.00005167129,0.002865637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004866304,"threshold_uncertainty_score":0.0162794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01852422061230272,"score_gpt":0.2875345803979591,"score_spread":0.2690103597856563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}